Summary
BeOne Medicines Ltd. (ONC) filed an 8-K report on September 20, 2021, detailing two significant corporate events. Firstly, on September 17, 2021, BeiGene, Ltd. announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the approval of BRUKINSA (zanubrutinib) for specific adult patient populations with Waldenström’s macroglobulinemia (WM). This positive opinion is a crucial step towards market access in Europe for this therapeutic. Secondly, the report highlights BeiGene's inclusion in several prominent FTSE Russell indices, effective September 17, 2021. These include the FTSE Global Equity Index Large Cap, FTSE All-World, FTSE All-Cap, and FTSE Total-Cap indices. Furthermore, BeiGene's commitment to sustainability is recognized through its inclusion in the FTSE Developed ESG Low Carbon Select Index and the FTSE Asia ex Japan ESG Low Carbon Select Index. These index inclusions can lead to increased investor visibility and potential for passive fund inflows.
Key Highlights
- 1Positive CHMP opinion recommending approval for BRUKINSA (zanubrutinib) for Waldenström’s macroglobulinemia (WM) in adults.
- 2BRUKINSA is indicated for adult patients with WM who have received at least one prior therapy or as first-line treatment for patients unsuitable for chemo-immunotherapy.
- 3This positive opinion is a significant regulatory milestone for BRUKINSA in the European market.
- 4BeiGene has been included in multiple FTSE Russell indices, including FTSE Global Equity Index Large Cap and FTSE All-World.
- 5Inclusion in FTSE Russell indices became effective on September 17, 2021.
- 6BeiGene's inclusion in the FTSE Developed ESG Low Carbon Select Index and FTSE Asia ex Japan ESG Low Carbon Select Index highlights its commitment to sustainability.